NGNE — Neurogene Inc. stock price, charts and financials

QT84Neurogene Inc.

Neurogene Inc. (NASDAQ: NGNE) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
34.41
+1.54+4.69%
OverviewShort InterestFilings
NGNEQT84Neurogene Inc.·NASDAQ
34.41+4.69%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
OCUL+2.26%$8.59MESO+2.28%$14.80AUPH+2.47%$14.93TYRA+1.53%$32.53URGN+3.45%$39.92IOVA+0.93%$4.36STOK+7.14%$31.67TSHA+7.27%$6.20
Snapshot
Index-P/E-EPS (ttm)-Insider Own38.87%Shs Outstand15.80MPerf Week3.58%
Market Cap543.76MForward P/E-EPS next Y-5.51Insider Trans-0.68%Shs Float12.54MPerf Month5.68%
Enterprise Value309.76MPEG-EPS next Q-Inst Own-Short Float23.36%Perf Quarter21.93%
Income-90.00MP/S0.00EPS this Y-Inst Trans-Short Ratio13.74Perf Half Y87.73%
Sales0.00P/B2.28EPS next Y-0.04%ROA-37.48%Short Interest2.93MPerf YTD67.04%
Book/sh15.06P/C2.24EPS next 5Y-ROE-37.88%52W High43.66 -21.19%Perf Year57.99%
Cash/sh15.38P/FCF-EPS past 3/5Y-ROIC-44.78%52W Low15.93 116.01%Perf 3Y152.64%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility5.04% 7.22%Perf 5Y-76.10%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-6.31%Oper. Margin0.00%ATR (14)2.29Perf 10Y-77.66%
Dividend Ex-Date-Quick Ratio13.08Sales Y/Y TTM-Profit Margin0.00%RSI (14)50.10Recom2.17
Dividend Gr. 3/5Y-Current Ratio13.08EPS Q/Q-28.70%SMA20-5.37%Beta1.64Target Price69.67
Payout0.00%Debt/Eq0.04Sales Q/Q-SMA506.10%Rel Volume0.68Prev Close32.87
Employees131LT Debt/Eq0.03EarningsAug 10SMA20036.20%Avg Volume210.16KPrice34.41
IPO DateMar 07, 2014Option/ShortYes / YesEPS/Sales Surpr.-7.23% -Net Debt/EBITDA1.21Volume142,208Change4.69%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-09-26ReiteratedHC Wainwright & Co.Buy$45 → $70
Jun-03-26InitiatedRodman & RenshawBuy$70
Apr-28-26InitiatedGuggenheimBuy$69
Oct-02-25ReiteratedH.C. WainwrightBuy$50 → $45
May-16-25DowngradeBairdOutperform → Neutral
Apr-14-25ReiteratedBMO CapitalOutperform$45 → $16
Mar-25-25ReiteratedRobert W. Baird$46 → $38
Mar-25-25ReiteratedHC Wainwright & Co.Buy$49 → $50
Nov-20-24ReiteratedStifel Nicolaus$60 → $46
Nov-12-24ReiteratedStifel Nicolaus$60
Latest News
Company

Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue0100000250
Cost of Goods Sold Incl. D&A3333422000
Gross Profit-3-2-3-3-42-20250
Selling, General and Administrative Excl. Other2523119815181615
Research and Development75614448422463336
Other Operating Expense0-4-3-4-421000
Operating Income-103-83-56-57-51-42-24-24-51
Interest Expense
000000000
Unusual Expense
—————————
Non-Operating Income (Expense)13719108-45-81
Net Income Before Taxes-90-75-36-55-51-33-69-32-50
Income Taxes
000000000
Consolidated Net Income-90-75-36-55-51-33-69-32-50
Net Income From Continuing Operations-90-75-36-55-51-33-69-32-50
Net Income-90-75-36-55-51-33-69-32-50
EPS (Recurring)-4.24-4.28-2.83-4.30-0.92-0.64-2.57-1.34-2.14
EPS (Basic, Before Extraordinaries)-4.24-4.28-2.83-4.30-0.92-0.64-2.57-1.34-2.14
EPS (Diluted)-4.24-4.28-2.83-4.30-0.92-0.64-2.57-1.34-2.14
EBITDA-87-72-33-52-50-31-69-32-50
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio—411.48—————41.47—
Gross Margin—-200.00—————100.00—
Operating Margin—-8,300.00—————-96.00—
Net Margin—-7,500.00—————-128.00—
Shares Outstanding211813135552272423
Market Capitalization4334112521325,30214,6646,6531,0375,410
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$47.02$37.96$28.90$19.83$10.77● Close Price0.00K93.27K186.53K279.80K373.06KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Cvijic Christine MikailPresident and CFOJul 07 '26Sale36.134,200151,76384,040Jul 07
Cvijic Christine MikailPresident and CFOJul 06 '26Sale36.0260021,61388,240Jul 07
Cvijic Christine MikailPresident and CFOJul 02 '26Sale34.824,061141,41688,840Jul 02
Cvijic Christine MikailPresident and CFOJul 01 '26Sale34.0673925,17092,901Jul 02
Cvijic Christine MikailPresident and CFOMay 06 '26Sale31.259,600300,04393,640May 08
Cvijic Christine MikailPresident and CFOMar 26 '26Sale21.622,55855,316103,240Mar 30
McMinn RachelChief Executive OfficerMar 26 '26Sale22.073,35273,9951,344,307Mar 30
Jordan JulieChief Medical OfficerMar 26 '26Sale21.8982818,12812,472Mar 30
Cobb StuartChief Scientific OfficerMar 13 '26Sale20.816,797141,44630,497Mar 17
Cvijic Christine MikailPresident and CFOMar 13 '26Sale20.814,04584,176105,798Mar 17
Cvijic Christine MikailPresident and CFOFeb 27 '26Sale25.114,800120,526109,843Mar 03
Cobb StuartChief Scientific OfficerMay 14 '25Sale15.156,797103,00320,794May 15
Cvijic Christine MikailPresident and CFOMar 13 '25Sale16.944,50176,24772,343Mar 17
Samsara BioCapital GP, LLC10% OwnerNov 26 '24Buy25.8348,7701,259,6231,717,127Nov 27
Cvijic Christine MikailPresident and CFONov 22 '24Buy20.4824,000491,40076,844Nov 25
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.